Role of pertussis toxin-sensitive G-protein, K+ channels, and voltage-gated Ca2+ channels in the antinociceptive effect of inosine

Purinergic Signalling

Volumn 9, Issue 1, 2013, Pages 51-58

  Macedo Junior, Sérgio José ^a   Nascimento, Francisney Pinto ^a   Luiz Cerutti, Murilo ^a   Santos, Adair Roberto Soares ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Calcium channels; Formalin test; Inosine; Pain; Pertussis toxin; Potassium channels

Indexed keywords

4 AMINOPYRIDINE; APAMIN; CALCIUM CHLORIDE; CHARYBDOTOXIN; DICLOFENAC; FORMALDEHYDE; G PROTEIN COUPLED RECEPTOR; GLIBENCLAMIDE; INOSINE; MORPHINE; PERTUSSIS TOXIN; POTASSIUM CHANNEL; TETRYLAMMONIUM; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; MALE; MOUSE; NOCICEPTION; NONHUMAN; PAIN;

EID: 84873749477     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-012-9327-2     Document Type: Article

References (50)

1. Barankiewicz J, Cohen A (1985) Purine nucleotide metabolism in resident and activated rat macrophages in vitro. Eur J Immunol 15: 627-631.
2. Mabley JG, Pacher P, Liaudet L, Soriano FG, Haskó G, Marton A, Szabo C, Salzman AL (2003) Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 284: 138-144.
3. Sawynok J, Liu XJ (2003) Adenosine in the spinal cord and periphery: release and regulation of pain. Prog Neurobiol 69: 313-340.
4. Hasko G, Sitkovsky MV, Szabó C (2004) Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25: 152-157.
5. Aviado DM (1983) Inosine: a naturally occurring cardiotonic agent. J Pharmacol 4: 47-71.
6. Jones CE, Thomas JX Jr, Devous MD, Norris CP, Smith EE (1977) Positive inotropic response to inosine in the in situ canine heart. Am J Physiol 233: 438-443.
7. Seesko RC, Zimmer GH (1990) Hemodynamic effects of inosine in combination with positive and negative inotropic drugs: studies on rats in vivo. J Cardiovasc Pharmacol 16: 249-256.
8. Gomez G, Sitkovsky MV (2003) Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 102: 4472-4478.
9. Garcia Soriano F, Liaudet L, Marton A, Haskó G, Batista Lorigados C, Deitch EA, Szabó C (2001) Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit Care Med 29: 703-708.
10. Marton A, Pacher P, Murthy KG, Németh ZH, Haskó G, Szabó C (2001) Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. Int J Mol Med 8: 617-621.
11. Nascimento FP, Figueredo SM, Marcon R, Martins DF, Macedo SJ Jr, Lima DAN, Almeida RC, Ostroski RM, Rodrigues ALS, Santos ARS (2010) Inosine reduces pain-related behavior in mice: involvement of adenosine A1 and A2A receptor subtypes and protein kinase C pathways. J Pharmacol Exp Ther 334: 590-598.
12. Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64: 1471-1483.
13. Jacobson KA, Gao GZ (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5: 247-264.
14. Sawynok J (1998) Adenosine receptor activation and nociception. Eur J Pharmacol 347: 1-11.
15. Cunha RA, Ferre S, Vaugeois JM, Chen JF (2008) Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 14: 1512-1524.
16. Fredholm BB, Cunha RA, Svenningsson P (2003) Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem 3: 413-426.
17. North RA (1989) Drug receptors and the inhibition of nerve cells. Br J Pharmacol 98: 13-28.
18. v3. 2 T-type channels revisited. Mol Pharmacol 77: 136-138.
19. Zamponi GW, Snutch TP (1998) Modulation of voltage-dependent calcium channels by G proteins. Curr Opin Neurobiol 8: 351-356.
20. Hylden JL, Wilcox GL (1980) Intrathecal morphine in mice. A new technique. Eur J Pharmacol 67: 313-316.
21. Hunskaar S, Fasmer OB, Hole K (1985) Formalin test in mice, a useful technique for evaluating mild analgesics. J Neurosci Methods 14: 69-76.
22. 2+ channels. Eur J Pharmacol 567: 198-205.
23. Ortiz MI, Lozano-Cuenca J, Granados-Soto V, Castañeda-Hernández G (2008) Additive interaction between peripheral and central mechanisms involved in the antinociceptive effect of diclofenac in the formalin test in rats. Pharmacol Biochem Behav 91: 32-37.
24. Hoehn K, Reid A, Sawynok J (1988) Pertussis toxin inhibits antinociception produced by intrathecal injection of morphine, noradrenaline and baclofen. Eur J Pharmacol 146: 65-72.
25. Prather PL, Loh HH, Law PY (1994) Interaction of delta-opioid receptors with multiple G proteins: a non-relationship between agonist potency to inhibit adenylyl cyclase and to activate G proteins. Mol Pharmacol 45: 997-1003.
26. Smart D, Hirst RA, Hirota K, Grand DK, Lambert DG (1997) The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca2+]i and adenylyl cyclase. Br J Pharmacol 120: 1165-1171.
27. Rodrigues AR, Duarte ID (2000) The peripheral antinociceptive effect induced by morphine is associated with ATP-sensitive K(+) channels. Br J Pharmacol 129: 110-114.
28. Dolphin AC, Prestwich SA (1985) Pertussis toxin reverses adenosine inhibition of neuronal glutamate release. Nature 316: 148-150.
29. Ocaña M, Cendán CM, Cobos EJ, Entrena JM, Baeyens JM (2004) Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 500: 203-219.
30. + channels by GTP-binding proteins in a mammalian cell line. J Physiol 507: 315-324.
31. Ocaña M, Baeyens JM (1994) Role of ATP-sensitive K+ channels in antinociception induced by R-PIA, an adenosine A1 receptor agonist. Naunyn Schmiedebergs Arch pharmacol 350: 57-62.
32. 1A receptors. Eur J Pharmacol 295: 181-188.
33. Gutman GA, Chandy KG, Aldeman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, Kuperschmidt S, Kurachi Y, Lazdunski M, Lesage F, Lester HA, McKinnon D, Nichols CG, O'Kelly I, Robbins J, Robertson GA, Rudy B, Sanguinetti M, Seino S, Stuehmer W, Tamkun MM, Vandenberg CA, Wei A, Wulff H, Wymore RS (2003) International Union of Pharmacology: XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev 55: 583-586.
34. + channels by meloxicam in the formalin test. Pharmacol Biochem Behav 81: 725-731.
35. Yalcin I, Asku F (2005) Involvement of potassium channels and nitric oxide in tramadol antinociception. Pharmacol Biochem Behav 80: 69-75.
36. Ortiz MI, Torres-López JE, Castañeda-Hernández G, Rosas R, Vidal-Cantú GC, Granados-Soto V (2002) Pharmacological evidence for the activation of K+ channels by diclofenac. Eur J Pharmacol 438: 85-91.
37. Lázaro-Ibáñez GG, Torres-López JE, Granados-Soto V (2001) Participation of the nitric oxide-cyclic GMP-ATP-sensitive K+ channel pathway in the antinociceptive action of ketorolac. Eur J Pharmacol 426: 39-44.
38. Alves D, Duarte I (2002) Involvement of ATP-sensitive K+ channels in the peripheral antinociceptive effect induced by dipyrone. Eur J Pharmacol 444: 47-52.
39. Ortiz MI, Granados-Soto V, Castañeda-Hernández G (2003) The NOcGMP-K+ channel pathway participates in the antinociceptive effect of diclofenac, but not of indomethacin. Pharmacol Biochem Behav 76: 187-195.
40. Déciga-Campos M, López-Muñoz FJ (2004) Participation of the l-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib. Eur J Pharmacol 484: 193-199.
41. Soares AC, Duarte ID (2001) Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(+) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol 134: 127-131.
42. Price M, Lee SC, Deutsch C (1989) Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc Natl Acad Sci 86: 10171-10175.
43. +-channels. Perspect Drug Disc Des 15(16): 15-40.
44. Hu H, Shao LR, Chavoshy S et al (2001) Presynaptic Ca2+-activated K+ channels in glutamatergic hippocampal terminals and their role in spike repolarization and regulation of transmitter release. J Neurosci 21: 9585-9597.
45. McGivern JG, McDonough SI (2004) Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 3: 457-478.
46. Vanegas H, Schaible H (2000) Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain 85: 9-18.
47. Yaksh TL (2006) Calcium channels as therapeutic targets in neuropathic pain. J Pain 7: S13-S30.
48. Prado WA (2001) Involvement of calcium in pain and antinociception. Braz J Med Biol Res 34: 449-461.
49. Cervero F, Laird JMA (2003) Role of ions channels in mechanisms controlling gastrointestinal pain pathways. Curr Opin Pharmacol 3: 608-612.
50. Ward DT (2004) Calcium receptor-mediated intracellular signalling. Cell Calcium 35: 217-228.